New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow
earlier and more detection of drug response in advanced NPC than RECIST method, in patients
with previously untreated advanced NPC who will receive platinum-based chemotherapy. This
study will also determine if this new method can predict survival in these patients. This
study may have far-reaching impact on drug development in NPC as it may offer a more optimal
way of evaluating drug efficacy in clinical trials and also in clinical management.